Quaker Partners
VC Fund
Philadelphia, United States
Quaker Partners is a healthcare investment firm focused on companies based on the U.S. East Coast.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Quaker Partners invests in
Stages Quaker Partners invests in
Countries Quaker Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Series B
- $7M–$39M
- Series C
- $20M–$35M
Investment Focus
Industry
- Health Care 6 (40%)
- Biotechnology 6 (40%)
- Medical Device 4 (27%)
- Therapeutics 3 (20%)
- Pharmaceutical 3 (20%)
Stage
- Series B 3 (20%)
- Series C 3 (20%)
- Funding Round 3 (20%)
- Series A 2 (13%)
- Seed 1 (7%)
Country
- United States 8 (53%)
- New Zealand 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
P. Sherrill Neff
Partner
|
Partner | Total investments: 3 | Find email | |
Brian Schwenk
CFO
|
CFO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Intact Vascular
|
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheralartery disease. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products.The company was founded in 2011 and is located at Wayne, PA, USA. | $25M / Series D / May 30, 2019 | |
Vesper Medical
|
Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them. The company's core technology, the Vesper DUO Venous Stent System, is purpose-built for venous stenting, with an unmatched combination of strength and flexibility designed to meet themultiple anatomical challenges presented by vein mechanics.Vesper Medical is advancing the treatment of deep venous disease by creating a highly differentiated, purpose-built venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins. It also develops minimally- invasive peripheral vascular products. Vesper Medical was founded in 2016 and is headquartered in Wayne, PA, USA. | $37M / May 29, 2019 | |
Vital
|
Keep patients more informed and engaged in the emergency room, hospital, and beyond. Vital’s AI-powered patient experience solutions give patients control, clarity, and predictability when they need it most. | $5.2M / Seed / Apr 24, 2019 | |
|
Vesper Medical
|
Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them. The company's core technology, the Vesper DUO Venous Stent System, is purpose-built for venous stenting, with an unmatched combination of strength and flexibility designed to meet themultiple anatomical challenges presented by vein mechanics.Vesper Medical is advancing the treatment of deep venous disease by creating a highly differentiated, purpose-built venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins. It also develops minimally- invasive peripheral vascular products. Vesper Medical was founded in 2016 and is headquartered in Wayne, PA, USA. | $10.5M / Series A / May 12, 2018 | |
|
Intact Vascular
|
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheralartery disease. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products.The company was founded in 2011 and is located at Wayne, PA, USA. | $20M / Series C / Apr 16, 2018 | |
TELA Bio
|
TELA Bio is a life science company that specializes in soft tissue reconstruction. The company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair. | $25M / Oct 30, 2017 | |
|
Intact Vascular
|
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheralartery disease. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products.The company was founded in 2011 and is located at Wayne, PA, USA. | $7.1M / Series B / Jan 03, 2017 | |
|
Intact Vascular
|
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheralartery disease. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products.The company was founded in 2011 and is located at Wayne, PA, USA. | $38.9M / Series B / May 14, 2015 | |
Rapid Micro Biosystems
|
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $25M / Series C / Apr 29, 2015 | |
Tarsa Therapeutics
|
Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction. | $7M / Series B / May 29, 2014 | |
| See all 15 investments → | |||
Co-Investors
H.I.G. BioHealth Partners
4 deals together
New Enterprise Associates
4 deals together
Longitude Capital
3 deals together
TVM Capital
3 deals together
Vensana Capital
2 deals together
Baxter Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Quaker Partners invest in?
Quaker Partners invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series C stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Quaker Partners's check size?
Quaker Partners typically joins rounds of $7M–$39M at Series B and $20M–$35M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Quaker Partners participates in.
How do I contact Quaker Partners?
Public channels for Quaker Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Quaker Partners?
The team at Quaker Partners includes P. Sherrill Neff (Partner) and Brian Schwenk (CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
